OctoPlus signs drug development contract with The Medicines Company

LEIDEN, NETHERLANDS, Jul 12 (MARKET WIRE) —
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces
today that it has signed a pharmaceutical development and manufacturing
contract with a new client, US-based The Medicines Company. The
undisclosed contract value will make a material contribution to OctoPlus’
annual revenues.

Under the contract terms, OctoPlus will perform process development and
clinical manufacturing for The Medicines Company related to MDCO-216
(ApoA-I Milano/phospholipid complex).

OctoPlus provides formulation development and clinical material
manufacturing services to biotech and pharmaceutical companies worldwide.
In addition to its expertise in formulation and manufacturing, OctoPlus
offers its clients drug delivery technologies for the development of
controlled release versions of existing or new drugs.

For further information, please contact:

Rianne Roukema, Corporate Communications: telephone number +31 (71) 524
1071 or send an e-mail to Investor Relations at IR@octoplus.nl.

About OctoPlus

OctoPlus is a drug delivery company committed to the creation of improved
pharmaceutical products that are based on OctoPlus’ proprietary drug
delivery technologies and have fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus focuses on the development of long-acting, controlled release
versions of known protein therapeutics, other drugs, and vaccines on
behalf of its clients.

The clinically most advanced product incorporating our technology is
Biolex Therapeutics’ lead product Locteron(R), a controlled release
formulation of interferon alpha for the treatment of chronic hepatitis C.
OctoPlus licensed Locteron exclusively to Biolex in October 2008.
Locteron is being manufactured for Biolex by OctoPlus and is currently in
Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the
pharmaceutical and biotechnology industries, with a focus on
difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol
OCTO. For more information about OctoPlus, please visit our website
www.octoplus.nl.

This document may contain certain forward-looking statements relating to
the business, financial performance and results of OctoPlus and the
industry in which it operates. These statements are based on OctoPlus’
current plans, estimates and projections, as well as its expectations of
external conditions and events. In particular the words “expect”,
“anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”,
“would”, “will”, “intend”, “believe” and similar expressions are intended
to identify forward-looking statements. We caution investors that a
number of important factors, and the inherent risks and uncertainties
that such statements involve, could cause actual results or outcomes to
differ materially from those expressed in any forward-looking statements.
In the event of any inconsistency between an English version and a Dutch
version of this document, the English version will prevail over the Dutch
version.

[HUG#1430917]

Click here for the press release in PDF:

http://hugin.info/137076/R/1430917/377483.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other
applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.

All reproduction for further distribution is prohibited.

Source: OctoPlus N.V. via Thomson Reuters ONE

Copyright 2010, Market Wire, All rights reserved.

OctoPlus N.V.: OctoPlus signs drug development contract with The Medicines Company

OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it
has signed a pharmaceutical development and manufacturing contract with a new client,
US-based The Medicines Company. The undisclosed contract value will make a material
contribution to OctoPlus’ annual revenues.

Under the contract terms, OctoPlus will perform process development and clinical
manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid
complex).

OctoPlus provides formulation development and clinical material manufacturing services
to biotech and pharmaceutical companies worldwide. In addition to its expertise in
formulation and manufacturing, OctoPlus offers its clients drug delivery technologies
for the development of controlled release versions of existing or new drugs.

For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or send an
e-mail to Investor Relations at IR@octoplus.nl.

About OctoPlus
OctoPlus is a drug delivery company committed to the creation of improved pharmaceutical
products that are based on OctoPlus’ proprietary drug delivery technologies and have
fewer side effects, improved patient convenience and a better efficacy/safety balance
than existing therapies. OctoPlus focuses on the development of long-acting, controlled
release versions of known protein therapeutics, other drugs, and vaccines on behalf of
its clients.

The clinically most advanced product incorporating our technology is Biolex
Therapeutics’ lead product Locteron, a controlled release formulation of interferon
alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively
to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is
currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and
clinical scale manufacturing services to the pharmaceutical and biotechnology
industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For
more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business,
financial performance and results of OctoPlus and the industry in which it operates.
These statements are based on OctoPlus’ current plans, estimates and projections, as
well as its expectations of external conditions and events. In particular the words
“expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”,
“would”, “will”, “intend”, “believe” and similar expressions are intended to identify
forward-looking statements. We caution investors that a number of important factors, and
the inherent risks and uncertainties that such statements involve, could cause actual
results or outcomes to differ materially from those expressed in any forward-looking
statements. In the event of any inconsistency between an English version and a Dutch
version of this document, the English version will prevail over the Dutch version.

Trials start on potent new hepatitis C drug

Washington, May 15 (ANI): Scientists have launched the first clinical trials on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation in western countries.

The current treatment involves two drugs – ribavirin and interferon, which has to be given as an injection. Side effects are often severe and lead to patients failing to complete the treatment.

The new drug, INX-189, is taken orally and was first prepared at the Welsh School of Pharmacy in November 2008.

Laboratory tests revealed that it killed 90 per cent of the virus at very low (nanomolar) concentration, making it one of the most potent compounds of its kind developed to date.

US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, has now started trials in healthy volunteers to assess the compound”s safety.

A second trial, which would evaluate the compound”s effectiveness on Hepatitis patients, may follow later this year.

“This is still a very early stage of the trials process. However, progress has been encouraging so far, going from the laboratory to human trials within 18 months. We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments,” said Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project. (ANI)

Skin cancer-treating prescription drug could boost effects of HIV vaccines

Washington, May 6 (ANI): A new weapon in the fight against hepatitis C and HIV is available in the form of a prescription drug, say researchers.

The drug already approved to treat genital warts and skin cancer can apparently boost the effectiveness of future vaccines for these bacterial and viral diseases.

John Pesce and colleagues at the Naval Medical Research Center and UC-Berkeley note that vaccines prepared from weakened or inactivated viruses or bacteria have had enormous success in preventing polio, influenza, and other diseases.

However, vaccines containing living or weakened viruses cannot be used for HIV, hepatitis C, and other devastating diseases due to safety concerns.

Scientists are instead trying to develop a new generation of vaccines, made with DNA or proteins from infectious agents that can prevent illness without carrying a risk of causing the diseases.

These vaccines will be weaker than conventional vaccines and require a new generation of ‘adjuvants,’ ingredients that boost a vaccine”s immunogenicity.

The report identifies a promising candidate in the form of imiquimod, an immune-boosting drug already in general use.

The scientists coated imiquimod with dextran-based microparticles in hopes of increasing the efficiency of cellular uptake by cells associated with immune response initiation.

Sure enough, the coated drug significantly boosted levels of inflammatory cytokines in laboratory cultures of immune cells from mice.

The findings have ‘broad significance’ and open the door to more extensive testing of the approach, they indicate.

These findings appear in ACS” Molecular Pharmaceutics, a bi-monthly journal. (ANI)

Extended hepatitis C treatment after liver transplant beneficial for patients

Washington, May 3 (ANI): A new study has shown that extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate.

“We found that patients who achieved a sustained virological response were more likely to have had extended treatment after transplant,” said Matthew Moeller, gastroenterology fellow at Henry Ford Hospital and lead author of the study.

“In the study, we saw a trend toward decreased mortality as sustained virological response was found to be associated with a 100 percent five-year survival rate vs. 86 percent for those without,” Moeller added.

Although, statistically insignificant, the trend could show significance with longer follow-up and a larger sample size, said Moeller.

As part of the study, the researchers looked at 241 consecutive liver transplant patients from 1999-2006. Patients were offered treatment if they tested positive for hepatitis C, had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable immunosuppression for a minimum of three months.

Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.

Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed.

This is in contrast to typical relapse rates of 30-35 percent in non-transplant patients treated with standard therapy. Genotype 1 patients failed more than genotype 2 or 3 patients in achieving sustained virological response (27 percent vs. 70 percent).

Dr. Moeller noted that 35 percent of patients who went on to achieve sustained virological response first became virus-negative at or following week 24.

“Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance with extended treatment,” said Dr. Moeller.

The results of the study were presented at the Digestive Diseases Week conference in New Orleans. (ANI)

UPDATE 2-InterMune gives promising mid-stage data on hep C drug

BANGALORE, April 14 (Reuters) – U.S. biotechnology company InterMune Inc (ITMN.O) reported encouraging results from a mid-stage trial of its experimental treatment for hepatitis C, sending its shares to their highest in eight years.

The company said serious adverse events were generally balanced across all treatment groups in the interim analysis of the study on danoprevir, which is being co-developed with Roche Holding AG (ROG.VX).

In November, InterMune had said it would discontinue testing in its 900 mg dose arm following elevated levels of ALT, an enzyme that indicates problems with the liver. [ID:nBNG443851]

“After November, I had completely written the drug off, but with today’s data they (InterMune) are back on the game,” said analyst Brian Skorney of ThinkEquity LLC.

Results from the study showed that the drug delivered virologic response in 88 percent of patients treated with 300 mg dosage for 12 weeks.

The company said 89 percent of the patients showed virologic response in the 600 mg dosage arm.

Analyst Skorney said he was impressed with the data, although tackling ALT elevation would be the biggest concern.

The company said in the treatment groups, ALT elevation occurred generally between weeks six to eight or later and this was reversible after the drug was discontinued.

The 12-week study in patients with chronic hepatitis C compared a combination of danoprevir and two standard-of-care anti-viral drugs with a dummy combination.

InterMune said it was now focused on making the critical dose and regimen selection decision for the development of the drug.

“Although ALT elevation is a problem that will be hard to overcome and a liver-toxic drug in hepatitis C is a hard sell, the real driver today was the feasibility of the drug for the treatment of hepatitis C,” analyst Skorney said.

“The question now is to see whether it can completely eliminate ALT elevation.”

InterMune shares were up 39 cents at $48.32 in morning trade Wednesday on Nasdaq. They touched a high of $49.05 in early trade. (Reporting by Krishnakali Sengupta; Editing by Vinu Pilakkott and Gopakumar Warrier)

Police investigate hep C infections

Victorian police are trying to find out whether a doctor deliberately infected 12 women with hepatitis C.

The women were all patients at a Melbourne abortion clinic between June 2008 and December 2009.

The state’s health department went public with its suspicions on Friday, but the department and the Victorian health minister are defending the decision to keep the matter quiet until now.

Suspicions were raised when the Victorian Department of Health noticed in December that three women diagnosed with hepatitis C had all been patients of the same clinic.

When a further nine cases were linked to the clinic early this year the department decided the police needed to be notified.

Victoria’s chief health officer, Dr John Carnie, says he cannot explain how 12 people could be infected by accident.

“I find it difficult to imagine how an accidental transmission could affect 12 patients and because of that difficulty we have tried to involve the police and the medical board in this investigation,” Dr Carnie said.

Dr Carnie would not say what sort of procedures the women had undergone, but it was confirmed today that the doctor is an anaesthetist.

He had been working at the clinic at Croydon in Melbourne’s outer-east.

The Victorian Health Department started testing the clinic’s staff in January, but at that time the doctor was overseas. He was tested on his return to Melbourne in early February.

Dr Carnie says it was confirmed the doctor had hepatitis C. Further testing, which Dr Carnie likens to testing fingerprints, showed that three of the women had the same strain of hepatitis C as the doctor.

It is known as genotype 1B and is a relatively rare form of the virus in Australia.

The Medical Practitioners Board declined to say if the doctor is from overseas.

Dr Carnie says the Victorian Health Department did a great job in identifying the hepatitis C cluster.

“We get over 2,000 cases of hepatitis C being notified to the Department. Out of those 2,000-odd cases in total, being able to find this very small number of cases that have this link to the clinic has been the result of very detailed and painstaking work on the part of the communicable disease area,” he said.

People who underwent surgery at the clinic between June 2008 and December 2009 are being contacted by the Department of Health.

But Dr Carnie will not speculate on the number of people that may have been infected.

“This whole episode is going to clearly cause distress in the community. I don’t want to add to that concern by starting to speculate on total numbers,” he said.

Of the 12 women who tested positive to hepatitis C, two have now cleared the virus from their bloodstreams, which Dr Carnie says is not unusual.

The other 10 women are at risk of developing cirrhosis of the liver or liver cancer.

But Dr Carnie says that anti-viral treatment can cure some cases.

Notification process

The doctor in question was suspended in mid-February after already giving the Victorian Department of Health an undertaking not to practice while the matter was being investigated.

Dr Carnie has defended the amount of time it took to suspend the doctor.

“From the time the clinic reopened after the holidays there was no ongoing risk to anyone and this person has not worked at that clinic since his return from overseas,” he said.

The President of the Victorian Medical Practitioners Board, Robert Adler, says doctors who have Hepatitis C are allowed to practice, but only if they follow infection control procedures and don’t do what are known as “exposure prone surgical procedures” like those in internal cavities or those with a higher risk of needle stick injury.

“Normal anaesthesia that follows infection control guidelines carries an extremely low or non-existent risk of transmission of Hepatitis C provided the doctor follows infection control guidelines,” he said.

The hepatitis C cluster was revealed in Melbourne’s Herald Sun newspaper this morning. Dr Carnie says it was not necessary to notify the public earlier.

“We are in the process of starting to call people back, other people who may have had procedures at this clinic and we didn’t want them to be alarmed by a call from the Department,” he said.

“We we wanted them to be aware of the issue that we’re dealing with and that was the reason for making this public.”

Victorian Health Minister, Daniel Andrews, says he was notified of the initial cluster of three cases of Hepatitis C on the December 22 last year.

He does not believe the public should have been notified earlier.

“I am confident that the chief health officer and my department, more broadly, have made appropriate contacts with Victoria Police and I’m confident that my department and the chief health officer have at all times, and at all stages, acted appropriately in relation to these issues,” Mr Andrews said.

Abortion clinic doctor infected women with hep C

Fears of a public health threat are being hosed down by authorities in Victoria after the revelation a doctor has been suspended from practice because 12 of his female patients have contracted Hepatitis C.

The anaesthetist has the disease and police and the Medical Practitioners Board are investigating how it was transmitted to the women.

The Department of Human Services says DNA tests have linked the strain of the virus found in the women to the strain the doctor has.

The doctor has not been named, but he was working at an abortion clinic in Melbourne between June 2008 and December 2009.

Critics say the public should have been notified about the possibility of infection far sooner.

Hepatitis C takes a long time to surface. It can cause fatal liver problems and is very hard to treat.

People with the infection can pass it on if their blood gets under the skin or into the bloodstream of another person, possibly through the use of a shared syringe.

In this instance the anaesthetist passed his Hepatitis C onto 12 women, many of whom were pregnant when they were infected with the disease between June 2008 and December last year.

At the time the anaesthetist was working at the Croydon Day Surgery in outer east Melbourne.

Health authorities do not know how it happened. They do not believe anyone else has been infected but they cannot guarantee it.

Victoria’s chief health officer, Dr John Carnie, says other people who visited the surgery are being tested.

“I mean I am pretty confident that if there were any other notified cases we would have picked them up. But for completeness sake we are going to call these other people back and get them tested as well,” he said.

Accident or deliberate?

Dr Carnie says he cannot explain how 12 people could be infected by accident.

“Accidents might involve say one or two patients, but we are dealing with a cluster of 12 patients. So at this stage there is nothing in the processes and procedures at this clinic that would enable me to explain how it happened,” he said.

He says investigations began in December when three people presented with Hepatitis C who had each been treated at the clinic over a six-month period.

Officers asked for all staff involved in surgical procedures to be tested.

“All of the staff at the time tested negative except for one of their medical practitioners who happened to be overseas at that time,” Dr Carnie said.

“So on that person’s return from overseas we arranged for that person to be tested – and this was at the beginning of February – and the results were clear, the person was Hepatitis C positive.

“We then asked the lab to conduct what are called sequencing studies. What it means is comparing the structure of a virus that you get from patients and comparing that structure with the virus that was obtained from the doctor concerned; similar to I guess doing a kind of fingerprint matching if you like.

“And the laboratory has found that there is a clear link from a structural point of view between the viruses of the three patients that we initially identified and that of the doctor.”

Notification criticism

There are concerns authorities took too long to notify the public about the possibility of infection.

National president of the Maternity Coalition, Lisa Metcalfe, says it has taken a long time for authorities to act and women are vulnerable.

“Where medical practitioners have been acting inappropriately and it has taken the Health Department some time – I mean 12 cases is a lot of women to be exposed to this kind of alleged abuse,” she said.

“It has taken a long time for them to actually act on it and to have effect, take effect and to do something about reining these medical practitioners in.”

In 2008 in the United States a district health authority in Nevada issued a public warning and called on people who had used a Las Vegas clinic over a four-year period to be tested for Hepatitis C and HIV.

The warning came after an investigation found the clinic had been responsible for unsafe anaesthesia injection practices.

The Southern Nevada Health District identified six cases of Hepatitis C at the clinic, five of which stemmed from procedures on the same day involving anaesthesia.

It said a syringe that was used to administer anaesthetics to one patient may have contaminated the vial from which the anaesthetics were drawn. Intended for single use only, the vial was subsequently reused.

The district advised 40,000 patients to contact their doctors and get tested for the disease.

Nothing like this happened in Victoria. Instead authorities went to the clinic and asked for a record of patients. Officials are gradually going through the list and contacting patients one by one.

Chief health officer Dr John Carnie says they did not want to alarm members of the public by issuing a warning in the first place back in February.

“We are in the process of starting to call people back, other people who may have had procedures at this clinic,” he said.

“We didn’t want them to be alarmed by a call from the department but we wanted them to be aware of the issue that we are dealing with, and that was the reason for making this public.”

Potential new target for treating hepatitis C identified

Washington, Mar 30 (ANI): A team of researchers has discovered that binding of a potent inhibitor of the hepatitis C virus (HCV) to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

This discovery, published in the March 29 early edition of the Proceedings of the National Academy of Sciences, provides a potential new target for structure-based design of new hepatitis C treatments.

Currently, the most effective treatment for hepatitis C is an agent called pegylated interferon, which is often combined with an antiviral drug called ribavirin.

“The available therapies for hepatitis C infection have limited effectiveness, with less than a 50 percent response,” says Darrell R. Davis, Ph.D., the lead author and professor and interim chair of medicinal chemistry and professor of biochemistry at the University of Utah. “However, small molecules that inhibit viral replication have been reported and they represent potential opportunities for new, more effective HCV treatments.”

HCV is a member of the Flaviviridae family of viruses, which also includes the viruses that cause yellow fever and dengue. There are six major genotypes of HCV, which differ slightly in their genetic constitution and vary in their response to treatment. HCV has a single strand of ribonucleic acid (RNA) as its genetic material and the virus replicates by copying this RNA. Previous research has shown that the three-dimensional structure of HCV RNA appears to be crucial for initiating the viral replication process.

Davis and his colleagues, including scientists from Isis Pharmaceuticals Inc., in Carlsbad, Calif., studied a potent small-molecule HCV replication inhibitor called Isis-11 to understand how it inhibits viral replication. They discovered that Isis-11 binds to a region of the viral RNA that is common to all six genotypes of HCV, altering the structure in a way that likely prevents the synthesis of viral proteins. The Isis-11 inhibitor effectively eliminated a bent RNA conformation that other laboratories have shown is required for the proper function of the HCV genomic RNA.

“Binding of Isis-11 resulted in a major conformational change in a specific region of HCV RNA that is thought to be critical for viral replication,” says Davis. “This alteration in structure provides a possible mechanism for the antiviral activity of Isis-11 and other HCV replication inhibitors in that chemical class.” (ANI)

Natalie Cole makes comeback after kidney transplant op

Washington, September 11 (ANI): R andB singer Natalie Cole made a comeback to the stage and performed at a concert in Hollywood after fighting severe health conditions for almost a year.

“I really do have to say … it really is a miracle time. It’s a miracle night for me. I never thought I’d be standing here healthy and whole and 100 percent,” People magazine quoted her as telling the crowd present.

The singer was diagnosed with Hepatitis C in April last year.

Apart from treating the liver disease with chemotherapy, she also battled kidney problems later that year.

However, she was back with a bang at the Hollywood Bowl belting out hits like ‘This Will Be,’ ‘Our Love,’ and ‘Unforgettable’

She said: “My heart is very full tonight, and I know a lot of you know why. It’s just good to be back. You know what I’m saying?

“You know, things don’t always go the way we want it to. Things happen unexpectedly. You got to take the good with the bad.”

Cole also brought the attention of the audience to health problems.

She said: “One in eight people has kidney failure. That’s a lot of people and I never thought it would happen to me, but here we are.”

She described the phase she was ill as “a real tough journey.” (ANI)

Satyam founder Raju placed under medial observation for 48 hours

Hyderabad, Sep 8 (ANI): Satyam Computers founder B Ramalinga Raju, who suffered a massive heart attack on Monday, has been put under observation for next 48 hours in the Intensive Care Unit (ICU) of the Nizam’s Institute of Medical Sciences (NIMS) hospital.

According to hospital sources, Raju has also been diagnosed with the Hepatitis C.

Doctors said, Raju’s condition is stable and that he needed rest for a long period.

According to jail sources, Raju suffered a cardiac arrest at around 8 p.m, was initially attended by the jail doctors before being shifted to NIMS hospital.

Raju, who has been under judicial custody at the Chanchalguda jail for the past eight months in connection with Rs 8,000 crore corporate fraud, facing criminal charges including fraud, forgery, cheating, embezzlement and insider trading along with his brother and Satyam’s former managing director Rama Raju and others.

Raju, will turn 55 on September 16.

Raju was Satyam’s Chairman until January 7, 2009 when he resigned from the company’s board after admitting to corporate fraud. The Andhra Pradesh Police arrested him on January 9.

Satyam was created by Raju and others and was until recently perceived to be among the top Indian IT companies. (ANI)

‘Ridiculously drunk’ mom knees daughter’s school principal in the groin

Melbourne, Jun 25 (ANI): A woman, who was in a very inebriated state, could not recall punching, spitting and kneeing her daughter’s school principal in the groin.

Karen Lee Pommer, 47, attacked Jeff Munce when she went to pick up her eight-year-old daughter from Warrigal Road State School in the Brisbane suburb of Eight Mile Plains on October 31 last year.

The Brisbane District Court was told on June 25 that Pommer entered the school grounds screaming obscenities while the students waited to be collected at the end of the day.

When Munce approached her she punched his head repeatedly, then kneed him in the groin and spat in his face.

She also slapped and spat at another mother who tried to intervene.

The court was told Pommer – who was infected with hepatitis C – then spat at and bit three police officers who arrived to arrest her.

None of her victims contracted the highly infectious disease.

When she was hauled into the police vehicle, she then wriggled free from her handcuffs and smashed one of the windows.

Defence barrister Jann Taylor said Pommer, a chronic alcoholic, had been suffering an “alcohol-induced blackout”‘ when she went to the school.

“She was ridiculously drunk to the point of no recollection,” News.com.au quoted Taylor as saying.

Pommer pleaded guilty to 10 offences including three counts of serious assault and two of common assault.

Judge Leanne Clare sentenced her to two years’ jail but released her on parole immediately. (ANI)

Natalie Cole ‘discharged from hospital’

Washington, May 26 (ANI): Singer Natalie Cole has reportedly been released from the hospital after undergoing a kidney transplant and is said to be recuperating.

Natalie, who suffered a kidney failure caused by hepatitis C, was discharged five days after her kidney transplant.

“Natalie is continuing to do well under the circumstances,” People quoted Natalie’s representative, as saying.

Sadly for Natalie, who had planned to attend a private family memorial service for her sister Carol “Cookie” Cole, who passed away following a battle with lung cancer, had to undergo the life-saving organ transplant on the very same day.

Meanwhile, Natalie is expected to spend the next three to four months recuperating and will reorganize her tour dates in support of her album Still Unforgettable. (ANI)

Natalie Cole loses sister to death

New York, May 23 (ANI): Natalie Cole underwent a life-saving kidney transplant surgery in Los Angeles and returned to her ailing sister’s bed, only to learn she had passed away.

The 59-year-old singer had been with her dying sister, Carol “Cookie” Cole when she received an urgent call from medics, saying that a kidney had been arranged from a deceased organ donor and that she would have to undergo surgery immediately.

And as the eight-time Grammy Award-winner, who has been suffering from kidney failure, caused by the hepatitis C she contracted during her time as an intravenous heroin user, was receiving the life-saving transplant after a few hours, her elder sister left the world.

“Natalie was there with her at her bedside at 4 in the morning on Monday, and she got a phone call from her doctors that a kidney was ready for her,” the New York Post quoted Natalie’s younger sister, Timolin Cole, as saying.

“She said, ‘What do you mean? I can’t deal with that right now! I’m here with my dying sister!’ And they said to her, ‘No, ma’am. We’ve got to do it now. You’ve got to be at Cedars-Sinai in two hours.’

“I told her, ‘Natalie, this is God’s gift, and you’ve got to go now. Cookie would want this for you,’” she added.

Timolin continued: “This is all so surreal, and it is devastating.

“Our sister Cookie hadn’t been to a doctor in 30 years, and last week she went in and they found a cancerous spot on her lung. They had wanted to start chemo right away, but Cookie said no.”

Natalie’s publicist called the family’s life-and-death parallels “a tragic coincidence.” (ANI)

Natalie Cole recovering from kidney transplant

Washington, May 21 (ANI): Ailing singer Natalie Cole recently underwent a life-saving kidney transplant surgery in Los Angeles, and was “resting comfortably,” according to her representative.

The 59-year-old has been suffering from kidney failure, caused by the hepatitis C she contracted during her time as an intravenous heroin user.

The eight-time Grammy Award-winner, who has been getting treated since September last year, had been put on a waiting list for a replacement organ.

“The kidney came from a deceased organ donor through the regional organ procurement agency, One Legacy,” People magazine quoted her rep as saying in a statement.

Cole is expected to recuperate for the next three to four months and is allegedly planning to re-arrange her summer tour dates in support of her album Still Unforgettable. (ANI)

Women with hypothyroidism more prone to liver cancer

Washington, May 5 (ANI): Women who have a history of hypothyroidism may be at an increased risk of developing liver cancer, according to a study.

Hypothyroidism is a disease that could lead to hyperlipidemia and weight gain, and may play a role in the development of nonalcoholic steatohepatitis, which can progress to more severe liver disease.

Many studies have shown that hypothyroidism is linked with hepatitis C, which in turn leads to a rising rate of liver cancer.

Led by Manal Hassan of Anderson Cancer Center at the University of Texas, the research team designed a case-control study to better understand the association between hypothyroidism and the development of liver cancer, also known as hepatocellular carcinoma (HCC), in the U.S.

For their analysis, the researchers recruited 420 patients with liver cancer and 1,104 healthy controls.

From each subject, they gathered demographic data and information about liver cancer risk factors – like smoking, alcohol consumption and family cancer history. The team also questioned them about their history of thyroid conditions and obesity.

They provided blood samples that were tested for hepatitis B and hepatitis C.

About 15 percent of the liver cancer patients were found to have a history of thyroid disease, compared to about 12 percent of the healthy controls.

The researchers found that the subjects with a history of hypothyroidism had twice the risk of liver cancer.

However the relationship was only significant for females.

Women who had a prior history of hypothyroidism for more than 10 years had a three-fold higher risk of liver cancer, compared to those without a history of thyroid disorders.

There was no change in the association even after adjusting for obesity.

“Whether and why hypothyroidism causes HCC is not clear. However, the association between hypothyroidism and NASH can be explained by the underlying hyperlipidemia, decreased fatty acid oxidation insulin resistance and lipid peroxidation in patients with hypothyroidism,” wrote the authors.

And these conditions may make the patient susceptible to HCC development.

“Further studies among different populations are warranted to confirm the association between hypothyroidism and HCC and to identify the underlying biological mechanisms and the genetic predisposition factors that may contribute to susceptibility to HCC development in the presence of thyroid disorders,” concluded the authors.

The study has been reported in the latest issue of Hepatology. (ANI)

Added anti-viral boosts response, shortens hepatitis C treatment duration

London, April 30 (ANI): A new study, conducted by researchers at the Duke Clinical Research Institute (DCRI), has found that adding the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease.

“Standard treatment for the most common type of hepatitis C is 48 weeks of a combination of two drugs, peginterferon alfa-2a and ribavirin, which cures less than half of patients and has significant side effects that make it very difficult for some patients to continue their treatment,” said John McHutchison, M.D., a hepatologist and gastroenterologist and researcher at the DCRI, and lead investigator on this study.

“Our study found that by combining the standard therapy with the direct anti-viral drug telaprevir, we could reduce the duration of treatment by 50 percent, to 24 weeks, and, at the same time, improve the cure rate by 50 percent,” he added.

Telaprevir is a protease inhibitor that works by blocking an enzyme that the hepatitis C virus needs in order to replicate itself.

In a randomized, Phase IIb, double-blinded, 37-center study of telaprevir in combination with peginterferon alfa-2a and ribavirin, the researchers examined the responses of 250 patients on four trial arms.

The researchers measured rates of sustained viral response – or SVR – defined as 24 weeks during which the hepatitis C virus remains undetectable in the body after the completion of therapy.

“We observed that 67 percent of patients who received standard therapy for 48 weeks in conjunction with 12 weeks of telaprevir were cured of their hepatitis C,” McHutchison said.

“The rate was 61 percent in the group that took the standard therapy for only 24 weeks in combination with 12 weeks of telaprevir, suggesting that many patients may respond to treatment in only six months as compared to about eleven months, which is significant for this patient population, because the side effects of treatment can be so intense,” McHutchison added.

McHutchison said that the group, which received standard therapy for up to 48 weeks had a sustained viral response rate of 41 percent.

He said that the most frequently reported adverse side effect associated with telaprevir was a rash that was manageable in some patients, but caused others to discontinue the treatment.

The findings have been published in the April 30, 2009 issue of the New England Journal of Medicine. (ANI)

Natalie Cole fears she will run out of time before kidney transplant

London, April 28 (ANI): Natalie Cole is terrified that she may not have enough time on her hands to undergo a life-saving kidney transplant.

The 59-year-old singer has been suffering from kidney failure caused by the chronic liver disease Hepatitis C.

The eight-time Grammy Award-winner contracted the condition from her drug addiction during the 80s and is being treated since September last year.

Cole has been put on a waiting list for a replacement organ but she fears the transplant may never come and has now left her fate to the Almighty.

“At the moment, where it’s coming from, heaven only knows,” the Daily Star quoted her as telling Los Angeles Confidential magazine. (ANI)

Survival rate similar in HIV positive, negative patients after liver transplant

Washington, Apr 25 (ANI): A research team led by Indian origin scientist has found no difference in the survival rates of HIV positive and HIV negative patients after undergoing liver transplant.

After analysing 6,315 adult patients, the results showed no difference in survival rates at 1 and 5 years between HIV negative and HIV positive patients (86.5pct and 74pct versus 87.1pct and 78 pct), suggesting a good prognosis for HIV positive patients following liver transplant.

However, the study confirmed that co-infection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV.

The survival rates at 1 and 5 years were 73pct and 53pct in HIV positive patients with hepatitis C versus 87pct and 69pct in HIV negative patients with hepatitis C.

“Data on long term outcomes from liver transplantation in HIV patients is limited. These study results are valuable confirmation that selected HIV positive patients are as suitable candidates for liver transplant as HIV negative patients and should have similar access to treatment,” said Dr Kosh Agarwal, of the Institute of Liver Studies, Kings College Hospital, London.

“However, those patients with co-infection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV related liver disease.

“In the context of co-infection, these data emphasise the need to develop newer and more innovative treatment strategies.

“These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection,” the expert added.

The findings were presented at Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark. (ANI)

Diabetes, obesity, hypertension up mortality in hepatitis C patients

Washington, Apr 23 (ANI): Type 2 diabetes, obesity and hypertension are associated with overall and liver related mortality in hepatitis C (HCV) infected patients, a new research has claimed.

The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

In HCV-infected patients, the top three predictors of liver related mortality were having higher body mass index (BMI), presence of insulin resistance (IR) and elevated serum cholesterol. Overall mortality in HCV patients was most linked to metabolic syndrome, higher BMI and hypertension.

Metabolic syndrome is a combination of medical problems that increase risks of cardiovascular disease and diabetes.

Recent data have suggested that metabolic syndrome is associated with adverse outcomes in HCV patients. This study set out to assess which aspects of metabolic syndrome are of most risk to such HCV patients and to quantify their specific impact on mortality.

Professor Zobair Younossi MD, MPH from the Center for Liver Diseases at Inova Fairfax Hospital and the Executive Director of Betty and Guy Beatty’s Center for Integrated Research, Virginia, USA, who led the study, said: “Exploring the risk factors associated with adverse outcomes in HCV patients helps us to better understand the complex nature of this highly prevalent disease.

“This study shows a clear association between key components of metabolic syndrome and mortality in HCV patients and demonstrates the importance of lifestyle improvements and coaching in the management of HCV patients, to potentially minimise the onset and impact of metabolic syndrome and its associated mortality risks.”

Researchers in this study utilised the Third National Health and Nutrition Examination Survey (NHANES III) and Linked Mortality Files. HCV was defined as positive HCV RNA by PCR assay. Subjects without other causes of chronic liver disease such as presumed NAFLD with elevated serum aminotransferases, excessive alcohol use, elevated transferrin saturation and positive hepatitis Bs antigen were designated controls without liver disease. HCV patients were compared to HCV-negative individuals and controls without liver disease using Rao-Scott chi-square statistics.

Adjusted hazard ratios for overall mortality and cause-specific mortality were calculated for HCV patients using persons without HCV. The Cox proportional hazard model was used for calculation of AHR for independent risk factors, and for the presence of HCV as a potential risk factor for overall mortality and cause-specific mortalities.

The cohort included 15,866 individuals with complete data. (ANI)